SUPPLEMENTAL FIGURE LEGENDS

Supplemental Figure S1. Overall survival (OS) hazard ratios (HR) versus progression-free survival (PFS) HRs – Unweighted Analysis. (A) All selected trials. (B) First-line phase III trials. (C) Phase III trials with targeted therapies. (D) First-line phase III trials with targeted therapies. (E) Trials with anti-epidermal growth factor receptor (EGFR) therapy. (F) Trials with anti-EGFR therapy, WT KRAS subgroup (treatment arms reporting patients with mutant KRAS mCRC were excluded). The horizontal line represents an OS HR = 1; the vertical line represents the surrogate threshold effect (ie, the minimum PFS effect that predicts a significant OS effect).